Ex Vivo News and Research

RSS

Gamida Cell announces results from NiCord Phase I/II study on hematological malignancies

Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.

15 Feb 2013

Sucampo receives supplement approval from FDA for AMITIZA

Sucampo Pharmaceuticals, Inc. today announced that the Company received a supplement approval from the U.S. Food and Drug Administration (FDA) that removes pregnancy "warnings and precautions" and clarifies information regarding the use of AMITIZA (lubiprostone) by pregnant and/or nursing women. In addition, the FDA expanded the labeling text of the Mechanism of Action section in the prescribing information for AMITIZA.

30 Nov 2012

TransMedics closes $36 million financing round

TransMedics, Inc., the global leader in organ preservation technology, announced the closing of a $36 million financing round led by Abrams Capital with the participation of existing investors including Flagship Ventures, Hercules Technology Growth Capital and Kleiner Perkins Caufield & Byers.

27 Nov 2012

Functional profiling using EVA/PCD doubles response rate and improves survival in NSCLC patients

Functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) doubles the response rate and improves time-to-progression and survival in patients with advanced lung cancer, according to a Phase II clinical trial conducted by investigators at Rational Therapeutics and the MemorialCare Todd Cancer Institute and published in the October issue of Anticancer Research.

8 Oct 2012

CytoDyn announces update on feline immunodeficiency virus therapeutic antibody program

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it is presenting an update on its Feline Immunodeficiency Virus (FIV) therapeutic antibody program at the 19th West Coast Retrovirus meeting in Palm Springs, California.

8 Oct 2012

Life Technologies receives FDA clearance for OpTmizer CTS T-cell expansion media

Life Technologies Corporation today announced it has received FDA 510(k) clearance for its OpTmizer CTS T-Cell Expansion Tissue Culture Medium – a reagent that is now cleared as a Class II medical device and offers cost- and time-saving advantages for transitioning studies from the research bench to clinical trials.

28 Sep 2012

Wiley announces publication of 6-volume Encyclopedia of Drug Metabolism and Interactions

Wiley is pleased to announce publication of the state-of-the-art, 6-volume Encyclopedia of Drug Metabolism and Interactions.

25 Sep 2012

MU endocrinologist to receive American Heart Association lifetime achievement award

One of the first researchers to study the deadly link between cardiovascular disease and diabetes will receive an American Heart Association lifetime achievement award today at a ceremony in Washington, D.C. The award presented to University of Missouri endocrinologist James Sowers, MD, recognizes his more than 30 years of accomplishments as a physician, scientist and educator.

21 Sep 2012

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

Gamida Cell, a leader in adult stem cell expansion technologies and products, announced today that it has completed enrollment for a Phase I/II clinical trial of NiCord, the company's second pipeline product.

20 Sep 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

Arteriocyte receives NIH grant for use of NANEX platform in bone marrow transplant

Arteriocyte, a leading clinical stage biotechnology company developing cellular based therapies to treat human diseases, announced today the successful award of another grant by the National Institute of Health for the use of the NANEX platform in Hematopoietic Reconstitution Using Ex Vivo Expanded Umbilical Cord Blood CD34+ Stem Cells.

22 Aug 2012

European collaboration to design a biomimetic bioartificial liver

Medicyte, The Electrospinning Company and the Universities of Manchester and Pisa launch a European wide unique project with the aim to design a biomimetic bioartificial liver (Re-Liver). The company GABO:mi ensures professional project management.

2 Jul 2012

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Infinity Pharmaceuticals, Inc. today reported preclinical data for IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data demonstrate potent PI3K-delta and -gamma inhibition in biochemical, cellular and whole blood assays and activity in multiple preclinical models of inflammatory disease, including rheumatoid arthritis and asthma.

28 Jun 2012

Novel technique helps surgeons to remove 'inoperable' abdominal tumors

Abdominal tumors involving both roots of the celiac and superior mesenteric artery (SMA) are deemed unresectable by conventional surgical methods, as removal would cause necrosis of the organs that are supplied by those blood vessels.

2 May 2012

TGF-β molecule ramps up the immune system in some cases and suppress it in others

Loyola researchers are reporting surprising findings about a molecule that helps ramp up the immune system in some cases and suppress it in others.

16 Apr 2012

Non-invasive and longitudinal assessment of fat in animal disease models

Researchers are increasingly aware that fat in some parts of the body is more harmful than fat in other places. To help determine how obesity works, scientists turn to animal models and now, they are able to visualize how much fat their lab rats are carrying and where they are storing it.

5 Apr 2012

UCSD surgeons perform west coast's first ex-vivo liver resection

A team led by Alan Hemming, MD, transplant surgeon at UC San Diego Health System, has successfully performed the west coast's first ex-vivo liver resection, a radical procedure to completely remove and reconstruct a diseased liver and re-implant it without any tumors. The procedure saved the life of a 27-year old mother whose liver had been invaded by a painful tumor that crushed the organ and entangled its blood supply.

6 Jan 2012

Woman's ovarian cycle plays an important role in her susceptibility to infection

A new research report in the Journal of Leukocyte Biology suggests that a woman's ovarian cycle plays an important role in her susceptibility to infection.

4 Jan 2012

Promising results from Fate Therapeutics' ProHema Phase 1b trial on hematologic malignancies

Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy.

14 Dec 2011

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

Experts from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, presented their latest research findings about hematologic cancers at the 53rd ASH Annual Meeting and Exposition held December 10-13, 2011 in San Diego, California.